The JSMO and JSCO guidelines are Japan's oncology guidelines, especially strong for gastric, oesophageal, liver and biliary cancers where Japanese trials set global standards (D2 gastrectomy, S-1, endoscopic resection), and for Japan's own approvals through PMDA.
Japanese organ societies publish some of the most detailed surgical and endoscopic guidelines in oncology (JGCA gastric cancer treatment guidelines, 6th edition 2021; Japan Esophageal Society; JSH hepatocellular carcinoma), reflecting trials such as JCOG9501, ACTS-GC, SPIRITS and JCOG1109. Drug availability differs (S-1, nedaplatin, TAS-102 origin), and PMDA approvals sometimes precede FDA (e.g. entrectinib, nivolumab for gastric cancer, cabozantinib-nivolumab). JSMO's clinical guidance on comprehensive genomic profiling underpins Japan's national reimbursement of CGP panels (2019).
Shares Oesophageal cancer, Hepatocellular carcinoma, Gastric & gastro-oesophageal junction cancer and the tag guidelines.
Shares Japan Clinical Oncology Group (JCOG), National Cancer Center Hospital, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer.
Shares Japan Clinical Oncology Group (JCOG), National Cancer Center Hospital, Comprehensive genomic profiling, Oesophageal cancer.
Shares Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and the tag guidelines.
Shares Biliary tract cancer (cholangiocarcinoma) and the tag guidelines.
Shares Japanese Society of Medical Oncology, Japan Clinical Oncology Group (JCOG), National Cancer Center Hospital, Gastric & gastro-oesophageal junction cancer.
Shares Japan Clinical Oncology Group (JCOG), Comprehensive genomic profiling, Oesophageal cancer, Hepatocellular carcinoma.
Shares Gastric & gastro-oesophageal junction cancer and the tag guidelines.